In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Pharmaceuticals Inc.

www.alnylam.com

Latest From Alnylam Pharmaceuticals Inc.

Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied

Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m. 

Financing Business Strategies

Novartis And The Medicines Company: Five Things To Worry About

The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.

M & A Reimbursement

AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards

The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.

Commercial Companies

It Has Been A Long Farewell To The Medicines Company

The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.

Companies Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Alnylam Holding Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • John M Maraganore, PhD, CEO
    Jeff S Poulton, EVP, CFO
    Pushkal Garg, MD, CMO
    Barry Greene, Pres.
    Yvonne Greenstreet, COO
    Kevin Fitzgerald, PhD, SVP, CSO
  • Contact Info
  • Alnylam Pharmaceuticals Inc.
    Phone: (617) 551-8200
    300 Third St., 3rd. Fl.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register